A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion

Inclusion Criteria: * Participants with advanced solid tumors diagnosed by histopathology or cytopathology. * Moderate to large pleural effusions require intervention. * ECOG performance status: 0 to 2. * Life expectancy ≥ 3 months * Adequate organ function. * The serum pregnancy test of female participants of childbearing potential should be negative within 7 days prior to enrollment and must not be breastfeeding. With a fertile female/male must agree to use medically accepted non-pharmacological contraception during the study and for 6 months after the last dose. Exclusion Criteria: * Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion. * Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion. * Known allergies to the study drug or its excipient components. * Have participated in other clinical trials within 28 days prior to randomization. * Major surgery within 28 days prior to randomization. * Central nervous system metastatic disease, leptomeningeal disease, or cord compression. * Clinical unstable or uncontrolled concomitant cardiovascular, pulmonary, hepatic, renal or seizures diseases. * Active infections that require systemic treatment. * Have a history of organ transplantation. * Any further condition which, in the opinion of the Investigator, the participant is not suitable in the present study.